Tag: Pharmaceutical

Alentis
Europe

Alentis Appoints Jonathan Freve CFO

Jon brings more than 25 years of financial experience in the biotech sector BASEL, Switzerland – Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Jonathan (Jon) Freve has been appointed Chief Financial Officer effective immediately. Roberto Iacone, CEO of Alentis said, “Jon has a proven track record in successful IPOs, secondary offerings and … Continue reading Alentis Appoints Jonathan Freve CFO

Impact Newswire
pfizer
United States

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

Tuesday, August 27, 2024 – 06:45am NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll , a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. The new, end-to-end experience will support the millions of Americans affected annually by common illnesses like migraine, COVID-19 or flu, and those seeking to protect themselves with adult vaccinations. … Continue reading Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

Impact Newswire
OM1
United States

OM1 Appoints Catherine Richards as President

Richards to lead cross-functional teams, enhancing OM1’s impact on healthcare transformation through advanced data solutions BOSTON – OM1, the leader in real-world evidence generation and insights for life sciences, proudly announces the appointment of Catherine Richards, PhD, MPH, as its first President. Richards will oversee the Product, Engineering, Clinical Informatics, Client Services, Data Science, and Research teams. Her leadership will be pivotal in advancing OM1’s strategy, innovation, and … Continue reading OM1 Appoints Catherine Richards as President

Impact Newswire
Merck
United States

Merck Completes Acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates RAHWAY, N.J. – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck. “The … Continue reading Merck Completes Acquisition of EyeBio

Impact Newswire